CFHR5, C9, and MBL2, the second panel of biomarkers, displayed potential as biomarkers for assessing NSCLC metastasis; specifically, CFHR5 alone was significantly associated with the OS of NSCLC patients [137]. This evidence concerns the gene C9 and non-small cell lung carcinoma.